睿知中国医院研究地图
候选清单

即将招募胶质瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma

ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由山东省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07869524,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 3 岁 至 18 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed grade IV diffuse midline glioma by biopsy.

    入选标准第 3 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

    入选标准第 4 条

  4. Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L;

    入选标准第 7 条

    Platelet count ≥75 × 10\^9/L;

    入选标准第 8 条

    Hemoglobin ≥9 g/dL (90 g/L) or ≥5.6 mmol/L;

    入选标准第 9 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN);

    入选标准第 10 条

    Serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/min. For participants <18 years of age, the Schwartz formula is recommended for estimation of creatinine clearance;

    入选标准第 11 条

  5. Untreated active hepatitis B virus (HBV) infection, defined as hepatitis B surface antigen (HBsAg) positivity with an HBV-DNA level above the upper limit of normal of the laboratory at the participating study center.

    排除标准第 6 条

    HBV viral load <1,000 copies/mL (200 IU/mL) before the first study treatment; anti-HBV therapy should be administered throughout the study treatment period to prevent HBV reactivation;

    排除标准第 7 条

    Participants who are anti-HBc positive, HBsAg negative, anti-HBs negative, and have an undetectable HBV viral load do not require prophylactic anti-HBV therapy but must be closely monitored for HBV reactivation.

    排除标准第 8 条

    Active hepatitis C virus (HCV) infection, defined as HCV antibody positivity with an HCV-RNA level above the lower limit of detection.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07869524,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Written informed consent must be obtained before initiation of any study-related procedures.
  2. Male or female participants aged ≥3 years and ≤18 years.
  3. Histologically confirmed grade IV diffuse midline glioma by biopsy.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  5. No prior systemic anticancer therapy for the current locally advanced disease.
  6. Adequate organ function, meeting all of the following criteria:
  7. Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L;
  8. Platelet count ≥75 × 10\^9/L;
  9. Hemoglobin ≥9 g/dL (90 g/L) or ≥5.6 mmol/L;
  10. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN);
  11. Serum creatinine ≤1.5 × ULN and creatinine clearance ≥60 mL/min. For participants <18 years of age, the Schwartz formula is recommended for estimation of creatinine clearance;
  12. Adequate coagulation function; isolated laboratory abnormalities may be considered acceptable if judged by the investigator to be not clinically significant;
  13. Cardiac enzyme profile abnormalities may be considered acceptable if judged by the investigator to be not clinically significant;
  14. No severe symptoms of increased intracranial pressure, such as persistent vomiting or disturbance of consciousness, or such symptoms must be stable after dehydration therapy.

排除标准:Exclusion Criteria:

  1. Previous cranial radiotherapy.
  2. Estimated life expectancy of less than 3 months.
  3. Presence of other central nervous system tumors, such as metastatic tumors, or other malignancies, except for curatively resected basal cell carcinoma of the skin or papillary thyroid carcinoma.
  4. Current participation in another interventional clinical study.
  5. Contraindications to radiotherapy.
  6. Untreated active hepatitis B virus (HBV) infection, defined as hepatitis B surface antigen (HBsAg) positivity with an HBV-DNA level above the upper limit of normal of the laboratory at the participating study center.
  7. HBV viral load <1,000 copies/mL (200 IU/mL) before the first study treatment; anti-HBV therapy should be administered throughout the study treatment period to prevent HBV reactivation;
  8. Participants who are anti-HBc positive, HBsAg negative, anti-HBs negative, and have an undetectable HBV viral load do not require prophylactic anti-HBV therapy but must be closely monitored for HBV reactivation.
  9. Active hepatitis C virus (HCV) infection, defined as HCV antibody positivity with an HCV-RNA level above the lower limit of detection.
  10. Any severe or uncontrolled systemic disease, including:
  11. Any medical history, evidence of disease, treatment, or laboratory abnormality that may interfere with the study results or prevent the participant from fully participating in the study, or any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment because of potential risks.

引自 ClinicalTrials.gov, NCT07869524, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07869524,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07869524